Abstract
DARA IV is approved as monotherapy and in multiple combinations with standard-of-care regimens for MM. A previous phase 1b trial of a SC formulation of DARA with recombinant human hyaluronidase PH20 (rHuPH20; ENHANZE® drug delivery technology, Halozyme, Inc.) demonstrated similar efficacy to DARA IV and was well tolerated by patients. The phase 3 COLUMBA study evaluated safety and efficacy of DARA SC vs IV in RRMM patients. Median duration of administration was substantially shorter for DARA SC (5 min across all injections) than DARA IV (421, 255, and 205 min for first, second, and subsequent infusions).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
